For over twelve years, HSD3B1 has been studied in prostate cancer, where the adrenal-permissive allele is associated with enhanced extragonadal and intratumoral androgen synthesis, resistance to androgen deprivation therapies, and poor outcomes [2,4]. This evidence concerns the gene HSD3B1 and prostate carcinoma.